Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 10/20 | 0.48 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777082 | 0.95 | PPARD (0.51) | KDM4EALDH1A1KMT2APKMPPARD | |
| SCHEMBL1778805 | 0.91 | PPARD (0.55) | PPARDPPARGPPARA | |
| SCHEMBL1779432 | 0.90 | KDM4E (0.50) | KDM4EALDH1A1KMT2APKMPPARD | |
| SCHEMBL1777586 | 0.86 | ALDH1A1 (0.46) | KDM4EALDH1A1KMT2APKMPPARD | |
| SCHEMBL1775862 | 0.86 | PPARD (0.59) | KDM4EALDH1A1PPARDPPARGPPARA | |
| SCHEMBL1775961 | 0.86 | PPARD (0.53) | KDM4EALDH1A1PPARDPPARGPPARA | |
| SCHEMBL14419861 | 0.85 | HRH3 (0.52) | KDM4EPPARDPPARGPPARA | |
| SCHEMBL14420003 | 0.84 | PPARD (0.49) | ALDH1A1PPARDPPARGPPARA | |
| SCHEMBL1776492 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1PPARDPPARGPPARA | |
| SCHEMBL1245304 | 0.82 | PPARD (0.51) | PPARDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943612-B2 | Compounds that modulate PPAR activity, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-17 | — | — | US | claimed |
| US-20090048257-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC | 2009-02-19 | — | — | US | claimed |
| EP-1999098-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | High Point Pharmaceuticals, LLC (US) | 2008-12-10 | — | — | EP | claimed |
| WO-2007101864-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-09-13 | — | — | WO | claimed |
| US-7943612-B2 | Compounds that modulate PPAR activity, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943612-B2 | Compounds that modulate PPAR activity, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943612-B2 | Compounds that modulate PPAR activity, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090048257-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC | 2009-02-19 | — | — | US | disclosed |
| US-20090048257-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC | 2009-02-19 | — | — | US | disclosed |
| US-20090048257-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC | 2009-02-19 | — | — | US | disclosed |
| EP-1999098-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | High Point Pharmaceuticals, LLC (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007101864-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048257-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | PPARD, PPARG, PPARA | KDM4E 3754/4885ALDH1A1 1075/4885KMT2A 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.